Document Type

Article

Publication Date

2020

Abstract

In 2018, President Trump signed a federal "right to try" law, claiming that it would give desperately ill patients earlier access to unapproved medicines, by allowing the patient, doctor, and drug company to arrange for access without federal oversight. Critics of the law argued that it would not meaningfully increase access to experimental medicines, because federal oversight was not the obstacle in the first place. And they were correct. U.S. law already permitted companies to provide terminally ill patients with early access to unapproved medicines. The problem was instead that companies did not take advantage of this option. This Article offers new insights into U.S. law on early access, as well as the new rightto- try law, by offering a comparative perspective using French law. We explore the historical, legal, and cultural differences between France and the United States that may explain differences in their early access systems and why the right-to-try law emerged in one country but not the other. The differing approaches reflect in part differing reactions to arguments grounded in personal autonomy and patients' rights, when held up against utilitarian arguments for premarket approval and traditions of medical paternalism. Using the French experience, this Article also considers the possibility that the key to increasing use of expanded access in the United States might be financial: making it worthwhile for companies, by allowing them to profit from sales, and making the medicines and associated healthcare services free for patients through insurance coverage.

Share

COinS
 
 

To view the content in your browser, please download Adobe Reader or, alternately,
you may Download the file to your hard drive.

NOTE: The latest versions of Adobe Reader do not support viewing PDF files within Firefox on Mac OS and if you are using a modern (Intel) Mac, there is no official plugin for viewing PDF files within the browser window.